section name header

Pronunciation

floo-PEN-tiks-ol

Classifications

Therapeutic Classification: antipsychotics

Pharmacologic Classification: thioxanthenes

Indications

REMS


Action

  • Alters the effects of dopamine in the CNS. Has some anticholinergic and alpha-adrenergic blocking activity.
Therapeutic effects:
  • Diminished signs and symptoms of schizophrenia.

Pharmacokinetics

Absorption: Flupentixol dihydrochloride: 40% absorbed following oral administration; Flupentixol decanoate: slowly released from IM injection sites.

Distribution: Distributes to lungs, liver, and spleen; enter CNS; extensive tissue distribution.

Protein Binding: 99%.

Metabolism/Excretion: Mostly metabolized, metabolites do not have antipsychotic activity. Most metabolites are excreted in feces, some renal elimination.

Half-Life: Flupentixol dihydrochloride: 35 hr; Flupentixol decanoate: 3 wk.

Time/Action Profile

(antipsychotic effect)

ROUTEONSETPEAKDURATION
POwithin 2–3 days3–8 hr (blood level)8 hr
IM (depot)24–72 hr4–7 days (blood level)2–4 wk



Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CNS: dizziness, NEUROLEPTIC MALIGNANT SYNDROME

EENT: blurred vision

CV: extrapyramidal symptoms, tachycardia, hypotension, QT INTERVAL PROLONGATION, sedation, tardive dyskinesia, THROMBOEMBOLISM

GI: constipation, dry mouth, excess salivation, hepatotoxicity

GU: libido, urinary retention

Derm: photosensitivity reactions, rash, sweating

Endo: glucose intolerance, hyperprolactinemia, menstrual irregularity

Hemat: agranulocytosis, granulocytopenia, neutropenia

Metab: weight change

MS: osteoporosis (long term use)

Interactions

Drug-drug:

Route/Dosage

Availability

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

Canadian Brand Names

Fluanxol